CYTOO
Latest round
- Series C
Last raised
- Nov 2011
Total raised
- $11M
Investors
- 5
About CYTOO
CYTOO, headquartered in Grenoble, France, specializes in delivering advanced solutions for muscle pathology research. The company was founded by Matthieu Piel and has undergone strategic pivots to enhance its offerings.5 million with Entrepreneurs Fund Management leading the investment alongside Auriga Partners.CYTOO specializes in advanced muscle pathology research and drug discovery solutions through its MyoScreen platform. This unique, integrated system enables the modeling of muscle diseases, identification of therapeutic targets, and validation of compounds, ultimately facilitating accelerated drug development processes. The core offerings include disease modeling, target identification and validation, hit identification and confirmation, lead profiling, and functional potency assays for batch release. These products aim to address genetic, metabolic, and neuromuscular disorders, providing significant insights for pharmaceutical companies and research institutions.CYTOO generates revenue through a structured model that includes partnerships and direct transactions with clients in the pharmaceutical and biotechnology sectors. In 2021, the company reported revenue of EUR 5,409,948 and an EBITDA of EUR 2,274,414. The flagship offerings, such as the MyoScreen platform and associated products like CYTOOchips and CYTOOplates, are integral to the drug discovery process and are sold on a project basis or via subscription agreements.5 million, secured in November 2011, to enhance its MyoScreen platform and develop new products aimed at expanding its market reach. The company is targeting entry into new geographical regions including Asia and North America by 2023. These initiatives will be supported by investments in product development and marketing strategies to increase visibility and accessibility of their offerings in the competitive biotechnology landscape.
Who invested in CYTOO
5 investors across 3 rounds
See all investors in CYTOO
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CYTOO
Who invested in CYTOO?
CYTOO has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CYTOO raised?
CYTOO has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did CYTOO last raise money?
CYTOO's most recent round on record is a Series C, in Nov 2011.
What does CYTOO do?
CYTOO, headquartered in Grenoble, France, specializes in delivering advanced solutions for muscle pathology research.
Where is CYTOO headquartered?
CYTOO is headquartered in Grenoble, France.
Which VCs invest in companies like CYTOO?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at CYTOO's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like CYTOO? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.